UBS Upgrades Jazz Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $179 From $145

 UBS upgraded Jazz Pharmaceuticals (JAZZ) to Buy from Neutral with a price target of $179, up from $145. The company's base business strength and Ziihera pipeline catalysts boost confidence that the stock warrants a higher multiple, the analyst tells investors in a research note.

https://www.marketscreener.com/quote/stock/JAZZ-PHARMACEUTICALS-PLC-9829261/news/UBS-Upgrades-Jazz-Pharmaceuticals-to-Buy-From-Neutral-Adjusts-Price-Target-to-179-From-145-49273603/